GlassScriptPhysician profile
Jeffrey Mullen
NPI 1447614276
$13,053.40
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 82% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $29.69 · 2023: $34.34 · 2024: $26.06 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,491 · Travel and Lodging: $1,978 · Food and Beverage: $1,284 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,491.36 |
| Travel and Lodging | $1,977.67 |
| Food and Beverage | $1,284.09 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $5,951.25 | 2023-2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $3,351.05 | 2022-2025 | |
| Genentech USA, INC. | $1,920.00 | 2025 | Evrysdi |
| Novartis Pharmaceuticals Corporation | $1,298.62 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $163.78 | 2021-2025 | |
| Nuvasive, INC. | $95.43 | 2021 | |
| Sarepta Therapeutics, INC. | $83.00 | 2025 | |
| Tanabe Pharma America, INC. | $54.64 | 2025 | Radicava |
| Octapharma USA, INC. | $36.63 | 2025 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $32.50 | 2025 | Zilbrysq, Rystiggo |
| Janssen Biotech, INC. | $32.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.10 | 2025 | Wainua |
| Csl Behring | $12.03 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.